Trans Signal Converter Proteins (TSCP) - based drugs for the
treatment of autoimmune diseases.
Overview
KAHR MEDICAL's technology and IP, which represents a
Click here to request more information, about this company (FOR COLLABORATION IN R&D. ONLY!)
Note - you have to be registered in this server to
request information. If you haven't done so
yet, please register in this server
Your requests will be forwarded to the developer, who
will contact you directly
You can also see the list of
documents you already requested more information about
paradigm-shift in protein-based therapeutics, is the result of
breakthrough discoveries by Professor Mark L. Tykocinski and by
his research team at the University of Pennsylvania. This team,
together with research teams at Hadassah Medical Center have
spent the last 8 years developing novel genetically engineered
fusion proteins that have great immuno-therapeutic potential for
a wide variety of autoimmune diseases..
KAHR's new drug pipeline is built around `trans signal converter
proteins (TSCP)' - a unique class of multi-functional therapeutic
agents that convert signals sent from one cell to another.
Conventional protein therapeutics consist of single functional
units that mediate single primary functions - for example, an
antibody functional unit blocking a specific receptor or ligand,
or a cytokine functional unit triggering a specific cognate
receptor. In contrast, KAHR MEDICAL's therapeutic proteins
integrate two functional units, enabling each one to elicit
multiple cooperative functional endpoints. Typically, each of
these fusion proteins connects a portion of a type I membrane
protein (at the fusion protein's N-terminus) with a portion of a
type II membrane protein (at the fusion protein's C-terminus).
The result is a therapeutic protein with superior activity and
specificity, with therapeutic benefits that cannot be achieved
simply by administering the fusion protein's component parts as
separate units. .
Several TSCP fusion proteins have been intensely studied and
their promise as drug candidates has been documented in multiple
scientific publications. KAHR MEDICAL has selected five of the
investigated TSCP candidates for its drug development pipeline,
two of which, TSCP-1 and TSCP-2, are currently in GMP cell-line
development towards clinical studies - planed to initiate in
2009.
